Urantide对动脉粥样硬化大鼠脾组织中ERK1/2及P38表达的影响

doi:10.13418/j.issn.1001-165x.2022.4.10

中国临床解剖学杂志 ›› 2022, Vol. 40 ›› Issue (4): 425-431.doi: 10.13418/j.issn.1001-165x.2022.4.10

Urantide对动脉粥样硬化大鼠脾组织中ERK1/2及P38表达的影响

胥玉行¹，李英¹，谢云鹏²，王途¹，崔海鹏¹，赵娟¹*

1.承德医学院病理生理学教研室，河北承德 067000； 2.承德医学院附属医院，河北承德 067000

收稿日期:2021-07-04 出版日期:2022-07-25 发布日期:2022-07-26
通讯作者: 赵娟，医学博士，教授，硕士生导师，E-mail：zhaojuan@cdmc.edu.cn
作者简介:胥玉行（1996-），男，四川射洪人，硕士研究生，E-mail：xuyuhang96@163.com
基金资助:
河北省自然科学基金（H2020406011）；河北省委组织部青年拔尖人才项目（冀组字[2016]9号）；河北省科技厅科技创新引导专项；河北省教育厅重点项目（ZD2019098）；承德医学院国家自然科学基金项目培育基金（201916）；承德医学院自然科学青年基金培育基金（KY202123）；河北省教育厅高校重点学科建设项目（冀教高[2013]4号病理学与病理生理学）；承德医学院2022年基本科研业务费课题（KY202227）

Effect of Urantide on the expression of ERK1/2 and P38 in the spleen of atherosclerotic rats

Xu Yuhang¹, Li Ying¹, Xie Yunpeng², Wang Tu¹, Cui Haipeng¹, Zhao Juan¹*

1. Department of Pathophysiology, Chengde Medical University, Chengde 067000, China; 2. Affiliated Hospital of Chengde Medical University, Chengde 067000, China

Received:2021-07-04 Online:2022-07-25 Published:2022-07-26

摘要/Abstract

摘要： 目的观察Urantide对动脉粥样硬化（atherosclerosis，AS）大鼠脾组织中MAPK信号通路ERK1/2和P38蛋白表达的影响，探究Urantide抗AS大鼠脾损伤的作用及机制。方法 180只Wistar大鼠随机分为：正常组，模型组，辛伐他汀组，Urantide 3 d、7 d、14 d组。HE染色观察大鼠胸主动脉、脾组织；免疫组织荧光染色、Western blot检测大鼠脾中ERK1/2、P38蛋白表达。结果 AS组与正常组相比，大鼠胸主动脉内出现典型AS病变，脾中央动脉出现玻璃样变，大鼠脾中p-ERK1/2、p-P38蛋白阳性表达升高（P<0.05）。Urantide各组与AS组相比，脾组织中玻璃样病变减轻，脾内p-ERK1/2、p-P38蛋白阳性表达降低，其中以Urantide 14 d组最明显（P<0.05）。结论 Urantide可通过抑制ERK1/2、P38的表达，发挥抗AS作用，进而改善AS大鼠脾组织病变程度。

关键词: 动脉粥样硬化； , , 脾； , , 尾加压素II； , , Urantide； , , MAPK； , , ERK1/2； , , P38

Abstract: Objective To observe the effect of Urantide on the expression of ERK1/2 and P38 in MAPK signaling pathway in spleen of atherosclerotic rats, and to explore the effect and mechanism of Urantide on ERK1/2 and P38 MAPK signaling pathway in spleen. Methods A total of 180 wistar rats were randomly divided into a normal group, an AS group, a Simvastatin group, a Urantide 3 days, 7 days and 14 days group. The thoracic aorta and spleen of rats were observed by HE staining. Immunofluorescence, Western blotting were used to detect the expression of ERK1/2 and P38 in the spleen of rats. Results Compared with control group, the HE staining of AS group showed typical AS pathological changes in thoracic aorta, and hyaline degeneration in the central artery of spleen, the positive expression of p-ERK1/2 and p-P38 protein in the spleen of rats significantly increased (P<0.05). Compared with AS group, the hyaline degeneration in spleen significantly reduced in Urantide groups and Simvastatin group, the positive expression of p-ERK1/2 and p-P38 protein in spleen significantly decreased, especially in the Urantide 14 days group (P<0.05). Conclusions Urantide can improve the degree of pathological changes in spleen of AS rats by inhibiting the expression of ERK1/2 and P38.

Key words: Atherosclerosis; , , Spleen; , , Urotensin Ⅱ; , , Urantide; , , MAPK; , , ERK1/2; , , P38

中图分类号:

R543.5

胥玉行, 李英, 谢云鹏, 王途, 崔海鹏, 赵娟. Urantide对动脉粥样硬化大鼠脾组织中ERK1/2及P38表达的影响[J]. 中国临床解剖学杂志, 2022, 40(4): 425-431.

Xu Yuhang, Li Ying, Xie Yunpeng, Wang Tu, Cui Haipeng, Zhao Juan. Effect of Urantide on the expression of ERK1/2 and P38 in the spleen of atherosclerotic rats[J]. Chinese Journal of Clinical Anatomy, 2022, 40(4): 425-431.

参考文献 34

[1]	Winkels H, Ehinger E, Vassallo M, et al. Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry[J]. Circ Res, 2018, 122(12): 1675-1688. DOI: 10.1161/CIRCRESAHA.117.312513.
[2]	Watanabe T, Sato K, Itoh F, et al. Emerging roles for vasoactive peptides in diagnostic and therapeutic strategies against atherosclerotic cardiovascular diseases[J]. Curr Protein Pept Sci, 2013, 14(6): 472-480. DOI: 10.2174/13892037113149990064.
[3]	Reustle A, Torzewski M. Role of p38 MAPK in atherosclerosis and aortic valve sclerosis[J]. Int J Mol Sci, 2018, 19(12): 3761. DOI: 10.3390/ijms19123761.
[4]	Mizumoto Y, Kyo S, Mori N, et al. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis[J].Cancer Sci, 2007, 98(5): 652-658. DOI: 10.1111/j.1349-7006.2007.00445.x.
[5]	崔海鹏, 刘凯, 李颖, 等. Urantide对动脉粥样硬化大鼠肝细胞外调节蛋白激酶1/2的作用及机制[J]. 解剖学杂志, 2019, 42(3): 235-239, 282. DOI: 10.3969/j.issn.1001-1633.2019.03.004.
[6]	孙晓旭, 王途, 许倩, 等. Urantide降低动脉粥样硬化大鼠胸主动脉中p38 MAPK表达[J]. 基础医学与临床, 2019, 39(9): 1283-1288. DOI: 10.3969/j.issn.1001-6325.2019.09.013.
[7]	Pereira-Castro J, Brás-Silva C, Fontes-Sousa AP. Novel insights into the role of urotensin II in cardiovascular disease[J]. Drug Discov Today, 2019, 24(11): 2170-2180. DOI: 10.1016/j.drudis.2019.08.005.
[8]	Suguro T, Watanabe T, Ban Y, et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension[J]. Am J Hypertens, 2007, 20(2): 211-217. DOI: 10.1016/j.amjhyper. 2006. 08.001.
[9]	Zhao J, Zhang SF, Shi Y, et al. Effects of urotensin II and its specific receptor antagonist urantide on rat vascular smooth muscle cells[J]. Bosn J Basic Med Sci,2013, 13(2): 78-83. DOI: 10.17305/bjbms. 2013.2369.
[10]	Zhao J, Miao GX, Wang T, et al. Urantide attenuates myocardial damage in atherosclerotic rats by regulating the MAPK signalling pathway[J]. Life Sci, 2020, 262(11): 118551. DOI: 10.1016/j.lfs. 2020. 118551.
[11]	张延辉, 郭晓辰, 张军平, 等. 脾调节动脉粥样硬化的相关机制研究[J]. 中国免疫学杂志，2017, 33(9): 1412-1414. DOI: 10.3969/j.issn. 1000- 484X.2017.09.029.
[12]	Wang YH， Huang ZY，Lu HX，et al. Apolipoprotein E-knockout mice show increased titers of serum anti-nuclear and anti-dsDNA antibodies[J]. Biochem Biophys Res Commun, 2012, 423(4): 805-812. DOI: 10.1016/j.bbrc.2012.06.044.
[13]	Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice[J]. Nat Biotechnol, 2011, 29(11): 1005-1010. DOI: 10.1038/nbt.1989.
[14]	Grasset EK, Duhlin A, Agardh HE, et al. Sterile inflammation in the spleen during atherosclerosis provides oxidation-specific epitopes that induce a protective B-cell response[J]. Proc Natl Acad Sci U S A, 2015, 112(16): E2030-E2038. DOI: 10.1073/pnas.1421227112.
[15]	Lucas AR, Korol R, Pepine CJ. Inflammation in atherosclerosis: some thoughts about acute coronary syndromes[J]. Circulation, 2006, 113(17): e728-e732. DOI: 10.1161/CIRCULATIONAHA.105.601492.
[16]	Viola J, Soehnlein O. Atherosclerosis-a matter of unresolved inflammation[J]. Semin Immunol, 2015, 27(3): 184-193. DOI: 10.1016/j.smim.2015.03.013.
[17]	Potteaux S, Ait-Oufella H, Mallat Z. Role of splenic monocytes in atherosclerosis[J]. Curr Opin Lipidol, 2015, 26(5): 457-463. DOI: 10.1097/MOL.0000000000000223.
[18]	Chistiakov DA, Grechko AV, Myasoedova VA, et al. The role of monocytosis and neutrophilia in atherosclerosis[J]. J Cell Mol Med, 2018, 22(3): 1366-1382. DOI: 10.1111/jcmm.13462.
[19]	Robbins CS, Chudnovskiy A, Rauch PJ, et al. Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions[J]. Circulation, 2012, 125(2): 364-374. DOI: 10.1161/CIRCULATIONAHA.111.061986.
[20]	Potteaux S, Gautier EL, Hutchison SB, et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression[J]. J Clin Invest, 2011, 121(5): 2025-2036. DOI: 10.1172/JCI43802.
[21]	赵依帆, 潘思京, 高真真, 等. 动脉粥样硬化的炎症信号通路研究进展[J]. 中华老年心脑血管病杂志, 2014, 16(12): 1332-1334. DOI: 10.3969/j.issn.1009-0126.2014.12.030.
[22]	徐瑞, 黄鹏, 张祎冰, 等. p38MAPK在动脉粥样硬化机制中的研究进展[J]. 中国老年学杂志, 2019, 39(17): 4365-4368. DOI: 10.3969/j.issn.1005-9202.2019.17.079.
[23]	杨翼鹰, 陈伟燕, 孙秀亭, 等. 麝香保心丸通过抑制p38 MAPK和NF-κB信号传导通路表达对抗高糖诱导的心肌细胞损伤[J]. 中国临床解剖学杂志, 2016, 34(5): 517-522, 527. DOI: 10.13418/j.issn.1001-165x. 2016.05.009.
[24]	Sun LF, An DQ, Niyazi GL, et al. Effects of Tianxiangdan Granule treatment on atherosclerosis via NF‑κB and p38 MAPK signaling pathways[J]. Mol Med Rep, 2018, 17(1): 1642-1650. DOI: 10.3892/mmr.2017.8067.
[25]	Cheng M, Yang LG, Fan M, et al. Proatherogenic stimuli induce HuR in atherosclerosis through MAPK/ErK pathway[J]. Am J Transl Res, 2019, 11(4): 2317-2327. PMID: 31105838.
[26]	Yang Y, Kim SC, Yu T, et al. Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses[J]. Mediators Inflamm, 2014, 2014: 352371. DOI: 10.1155/2014/352371.
[27]	McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance[J]. Biochim Biophys Acta, 2007, 1773(8): 1263-1284. DOI: 10.1016/j.bbamcr.2006.10.001.
[28]	Emtiazy M, Choopani R, Khodadoost M, et al. Atheroprotector role of the spleen based on the teaching of Avicenna (Ibn Sina)[J]. Int J Cardiol, 2013, 167(1): 26-28. DOI: 10.1016/j.ijcard.2012.06.020.
[29]	Akan AA, Sengül N, Simşek S, et al. The effects of splenectomy and splenic autotransplantation on plasma lipid levels[J]. J Invest Surg, 2008, 21(6): 369-372. DOI: 10.1080/08941930802438898.
[30]	Svistunov AA, Tarasov VV, Shakhmardanova SA, et al. Urotensin II: molecular mechanisms of biological activity[J]. Curr Protein Pept Sci, 2018, 19(9): 924-934. DOI: 10.2174/1389203718666170829162335.
[31]	Cui HP, Lin YX, Xie LD, et al. Urantide decreases hepatic steatosis in rats with experimental atherosclerosis via the MAPK/Erk/JNK pathway[J]. Mol Med Rep, 2021, 23(4): 284. DOI: 10.3892/mmr.2021.11923.
[32]	李英, 谢利德, 王途, 等. 多肽类化合物Urantide对动脉粥样硬化大鼠心脏组织中骨桥蛋白和α平滑肌肌动蛋白表达的影响[J]. 解剖学报,2021, 52(3): 446-452. DOI: 10.16098/j.issn.0529-1356. 2021. 03. 018.
[33]	Wang T, Xie LD, Bi HD, et al. Urantide alleviates the symptoms of atherosclerotic rats in vivo and in vitro models through the JAK2/STAT3 signaling pathway[J]. Eur J Pharmacol, 2021, 902: 174037. DOI: 10.1016/j.ejphar.2021.174037.
[34]	Wang T, Xie YQ, Miao GX, et al. Urotensin receptor antagonist urantide improves atherosclerosis-related kidney injury by inhibiting JAK2/STAT3 signaling pathway in rats[J]. Life Sci, 2020, 247: 11742. DOI: 10.1016/j.lfs.2020.117421.

Urantide对动脉粥样硬化大鼠脾组织中ERK1/2及P38表达的影响

Effect of Urantide on the expression of ERK1/2 and P38 in the spleen of atherosclerotic rats

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 34

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	江剑宏, 段仁鹏, 李晓锋. 国人胆道三维重建解剖变异应用研究[J]. 中国临床解剖学杂志, 2024, 42(1): 1-4.
[2]	郭红志, 王瑜, 张加琪, 梁海彬, 马梓玮, 冯伟, 吴忧, 司子燚. 血管铸型结合CT三维模型评估先兆子痫胎盘血管结构[J]. 中国临床解剖学杂志, 2024, 42(1): 5-10.
[3]	李佳伟, 张静, 李灿然, 兰文杰, 籍庆余, 郭志勇, 张云凤, 刘启, 陈清威, 李筱贺. 蒙古族人群股骨近端解剖参数X线测量[J]. 中国临床解剖学杂志, 2024, 42(1): 11-16.
[4]	李琨, 张燕, 郭冉, 郝咪咪, 吴轩宇, 徐艺芳, 王超群, 马文童, 张灵淇, 杨宏宇, 李志军, 张少杰, 王星. 儿童及青少年枕颈角与后枕颈角数字化测量及其临床意义[J]. 中国临床解剖学杂志, 2024, 42(1): 17-20.
[5]	李文, 杨思艺, 黄蕾, 卿霁雯, 蒋松涛, 张磊. 基于MRI探讨Lisfranc韧带的形态学特点及临床意义[J]. 中国临床解剖学杂志, 2024, 42(1): 21-25.
[6]	李凡凡, 徐阳, 王晓旭. 紫草素调节Nrf2/HO-1信号通路对实验性大鼠肉芽肿性小叶性乳腺炎的治疗作用研究[J]. 中国临床解剖学杂志, 2024, 42(1): 26-32.
[7]	王兴航, 丁佳媛, 李放, 包翠芬, 阎丽菁. 人参皂苷Rg1通过抑制NLRP3炎症小体途径减轻氧糖剥夺/复供后小胶质细胞炎症反应[J]. 中国临床解剖学杂志, 2024, 42(1): 33-41.
[8]	程莹莹, 武建军, 蔡海燕, 焦旭文, 马江波, 丁银秀. 体外炎性诱导星形胶质细胞激活及功能分析[J]. 中国临床解剖学杂志, 2024, 42(1): 42-46.
[9]	祁志, 杨力, 贾秋叶, 陈浩伦, 段兆达, 吴春云. 依达拉奉经MAPKs通路对脂多糖激活的小胶质细胞Sirt3表达调控[J]. 中国临床解剖学杂志, 2024, 42(1): 47-53.
[10]	张晶晶, 王洪新. 黄芩苷通过PDGF/P38 MAPK信号通路对肺动脉高压大鼠的保护作用[J]. 中国临床解剖学杂志, 2024, 42(1): 54-58.
[11]	乐钦, 陈荣丽, 熊婧熙, 王婷怡, 蔡志恒, 易秋实, 曾心怡. 白芨多糖对大鼠跨区皮瓣choke区的影响[J]. 中国临床解剖学杂志, 2024, 42(1): 59-64.
[12]	李笑予, 张磊, 付磊, 李东波, 汪国友. 三步接骨法治疗Sanders Ⅱ型跟骨骨折的有限元研究[J]. 中国临床解剖学杂志, 2024, 42(1): 65-70.
[13]	吴研飞, 马剑雄, 卢斌, 王颖, 柏豪豪, 靳洪震, 马信龙. CT后处理技术重建CT值与终板抗压强度的相关性研究[J]. 中国临床解剖学杂志, 2024, 42(1): 71-76.
[14]	庄万强, 唐毅, 骆勇刚, 张辉. 关节镜联合胫骨高位截骨术对髌骨位置及髌股关节功能影响的早中期回顾性研究[J]. 中国临床解剖学杂志, 2024, 42(1): 77-82.
[15]	罗鹰, 窦伟誉, 吴小杭, 陈璟昆, 彭昌贵, 潘剑英 . 微创海马钢板内固定治疗跟骨骨折并发症的影响因素[J]. 中国临床解剖学杂志, 2024, 42(1): 83-88.